NCT01970618View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Chronic Obstructive Pulmonary Disease (COPD)Healthy Volunteers
Interventions
DRUG

RV1162 single dose

Safety and tolerability of single escalating doses

DRUG

RV1162 matching placebo single dose

Safety and tolerability of single escalating doses

DRUG

RV1162: 7 day repeat dose

Safety and tolerability of a repeat dose

DRUG

RV1162 matching placebo: 7 day repeat dose

Safety and tolerability of a repeat dose

DRUG

RV1162: 14 day repeat dose

Safety and tolerability of repeat escalating doses

DRUG

RV1162 matching placebo: 14 day repeat dose

Safety and tolerability of repeat escalating doses

Trial Locations (1)

M23 9QZ

Manchester

All Listed Sponsors
lead

Respivert Ltd

INDUSTRY

NCT01970618 - Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients | Biotech Hunter | Biotech Hunter